Ketek--the FDA perspective.
Soreth
Janice
J
Cox
Edward
E
Kweder
Sandra
S
Jenkins
John
J
Galson
Steven
S
D026683:Advisory Committees; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D048628:Ketolides / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D015871:Scientific Misconduct; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin